Evan David Seigerman
Stock Analyst at BMO Capital
(3.13)
# 1,134
Out of 4,784 analysts
35
Total ratings
34.38%
Success rate
6.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $89.23 | +7.59% | 4 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $208 → $215 | $205.29 | +4.73% | 7 | Feb 3, 2025 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $27 | $10.39 | +159.87% | 3 | Jan 22, 2025 | |
| NVO Novo Nordisk | Maintains: Outperform | $156 → $105 | $69.30 | +51.52% | 5 | Dec 23, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,300 → $1,190 | $637.36 | +86.71% | 5 | Nov 1, 2024 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $83 → $100 | $19.77 | +405.82% | 2 | Jun 7, 2024 | |
| AMGN Amgen | Maintains: Outperform | $336 → $355 | $306.95 | +15.65% | 3 | May 3, 2024 | |
| PFE Pfizer | Reiterates: Outperform | $33 → $36 | $25.21 | +42.80% | 4 | May 2, 2024 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $5.95 | -49.54% | 1 | May 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $369 → $396 | $822.51 | -51.85% | 1 | Sep 6, 2022 |
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $89.23
Upside: +7.59%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $205.29
Upside: +4.73%
Replimune Group
Jan 22, 2025
Maintains: Outperform
Price Target: $18 → $27
Current: $10.39
Upside: +159.87%
Novo Nordisk
Dec 23, 2024
Maintains: Outperform
Price Target: $156 → $105
Current: $69.30
Upside: +51.52%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $1,300 → $1,190
Current: $637.36
Upside: +86.71%
Structure Therapeutics
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $19.77
Upside: +405.82%
Amgen
May 3, 2024
Maintains: Outperform
Price Target: $336 → $355
Current: $306.95
Upside: +15.65%
Pfizer
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $25.21
Upside: +42.80%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.95
Upside: -49.54%
Eli Lilly and Company
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $822.51
Upside: -51.85%